Guangyao Li

Guangyao Li

Auto-generated profile, based on publicly available information

Guangyao Li

Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
HTHuilin Tang
Huilin Tang
GLGuangyao Li
Guangyao Li
YZYing Zhao
Ying Zhao
FWFei Wang
Fei Wang
EGEmily W. Gower
Emily W. Gower
TWTiansheng Wang
Tiansheng Wang

26 July 2018 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
YZYing Zhao
Ying Zhao
TWTiansheng Wang
Tiansheng Wang
GLGuangyao Li
Guangyao Li
SSSun Shusen
Sun Shusen

21 May 2019 in Diabetes Care
Verified
Journal Article
Open access
PDF file
GLGuangyao Li
Guangyao Li
MCMatthew J. Crowley
Matthew J. Crowley
HTHuilin Tang
Huilin Tang
JYJeff Y. Yang
Jeff Y. Yang
RSRobert S. Sandler
Robert S. Sandler
TWTiansheng Wang
Tiansheng Wang
A recent retrospective cohort study found that new use of dipeptidyl peptidase 4 inhibitors (DPP4i) of 1.6 years was associated with an increased risk of inflam

12 October 2022 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
ZSzhaoran su
zhaoran su
KSKuanshan Shu
Kuanshan Shu
GLGuangyao Li
Guangyao Li
BACKGROUND: The prognostic role of annexin A5 (ANXA5) in stomach adenocarcinoma (STAD) has not been studied, and its relationship with immune infiltration is still unclear. OBJECTIVE: This investigation aimed at exploring the role of ANXA5 in STAD using an integrated bioinformatics analysis. METHODS: The expression of ANXA5 in STAD and the correlations between the effect of ANXA5 and survival of STAD patients were investigated using database. The clusterProfiler package in R software was used to perform enrichment analysis on the top 100 co-expressed genes of ANXA5 from the COXPRESdb online database. Correlations between ANXA5 and immune cell infiltrates were analyzed using the TIMER database. RESULTS: In STAD, ANXA5 expression was significantly upregulated and increased ANXA5 expression was significantly correlated with poor overall survival (P< 0.05). In multivariate analysis, upregulated ANXA5 expression was an independent predictive factors of poor prognosis (P< 0.05). The co-expressed genes were involved in extracellular matrix (ECM)-related processes. In STAD, ANXA5 expression was significantly correlated with various infiltrating immune cells (P< 0.05). CONCLUSIONS: Together with our findings, ANXA5 could serve as a potential biomarker to assess prognosis and immune infiltration level in STAD.

18 November 2024 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
YYYilong Yan
Yilong Yan
YBYing Bai
Ying Bai
JWJiawei Wang
Jiawei Wang
GLGuangyao Li
Guangyao Li
1. Gout is a prevalent medical illness characterized by the accumulation of sodium urate crystals in both joint and non-joint tissues, resulting in periodic episodes of intense and debilitating art...

1 October 2009 in The Journal of Alternative and Complementary Medicine
Verified
Journal Article
Closed access
JLJi-Zhu Liu
Ji-Zhu Liu
SCShou-Guo Chen
Shou-Guo Chen
BZBin Zhang
Bin Zhang
CWChunbo Wang
Chunbo Wang
XZXiao-Wen Zhao
Xiao-Wen Zhao
WWwanglexin wang
wanglexin wang
The purpose of this study was to investigate the effect of Haishengsu, an extract from Tegillarca L. granosa, on the effects and side-effects of immunotherapy in patients with advanced renal cell cancer. Fifty-five (55) patients with renal cell cancer were randomly divided into a Haishengsu group (n = 27, 2.4 mg, intravenously for 15 days) and a control group (n = 28). All patients were also treated with interleukin-2, interferon-alpha, and fluorouracil. In the Haishengsu group, the prevalence of gastrointestinal reactions to the immunotherapy was lower than in the control group (18.5% versus 64.3%, p < 0.01). In comparison with the control group, more patients from the Haishengsu group had increased food intake (74.1% versus 14.3%, p < 0.01), weight gain (77.8% versus 10.7%, p < 0.01) or an increase in Karnofsky Performance Status score (55.6% versus 17.9%, p < 0.01). The remission rate of cancer in the Haishengsu group was higher than in the control group (51.9% and 21.4%, p < 0.01). Addition of Haishengsu to the conventional immunotherapy is associated with an increased remission rate in patients with advanced renal cell cancer. Haishengsu was also associated with a reduced rate of gastrointestinal side-effects from the immunotherapeutic agents, and an improvement in the physical functionality of the patients.